Back

Leads Biolabs’ opamtistomig study selected for ESMO 2026 late-breaking presentation

Verifying
  • Leads Biolabs secured an ESMO 2026 late-breaking presentation for its opamtistomig EP-NEC study.
  • The Phase IIb trial covers patients receiving at least two prior systemic-therapy lines.
  • Three Leads Biolabs studies received Proffered Paper selections at ESMO 2026.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.